Key result
AGTR1 A1166C polymorphism shows no significant association with chronic kidney disease risk.
Why the study?
Is the AGTR1 A1166C genetic polymorphism associated with an increased risk of chronic kidney disease or end-stage renal disease in adults?
Meta-Analysis (n=14,823)
Yes
Is the AGTR1 A1166C genetic polymorphism associated with an increased risk of chronic kidney disease or end-stage renal disease in adults?
This combined case-control study and meta-analysis demonstrates that the AGTR1 A1166C polymorphism is not associated with CKD risk in East Asian or Caucasian populations, though a potential association in Indian populations warrants further study.
Answers are grounded in this paper and cite their sources.
No support for AGTR1 A1166C genotyping in CKD risk assessment; leaves open possible Indian-population effects for targeted study.
// Hsien-Feng Chang 1 , Po-Jen Hsiao 2, 3, 4 , Yu-Juei Hsu 2 , Fu-Huang Lin 1 , Chin Lin 1 , Wen Su 5 , Hsiang-Cheng Chen 6, * and Sui-Lung Su 1, * 1 School of Public Health, National Defense Medical Center, Taiwan, ROC 2 Division of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taiwan, ROC 3 Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taiwan, ROC 4 Big Data Research Center, Fu-Jen Catholic University, Taiwan, ROC 5 Department of Nursing, Tri-Service General Hospital, Taiwan, ROC 6 Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taiwan, ROC * These authors have contributed equally to this work Correspondence to: Sui-Lung Su, email: a131419@gmail.com Hsiang-Cheng Chen, email: hccheng@ndmctsgh.edu.tw Keywords: angiotensin II receptor type 1; AGTR1 A1166C; chronic kidney disease; meta-analysis; gene-environment interaction Received: June 08, 2017 Accepted: February 03, 2018 Epub: February 12, 2018 Published: March 06, 2018 ABSTRACT Studies of the association between angiotensin II receptor type 1 A1166C (AGTR1 A1166C) polymorphism and chronic kidney disease (CKD) risk have yielded conflicting results. We conducted a combined case-control study and meta-analysis to better define this association. The case-control study included 634 end-stage renal disease (ESRD) patients and 739 healthy controls. AGTR1 A1166C genotype was determined using polymerase chain reaction and iPLEX Gold SNP genotyping methods. The meta-analysis included 24 studies found in the PubMed and Cochrane Library databases. Together, the case-control study and meta-analysis included 36 populations (7,918 cases and 6,905 controls). We found no association between the C allele and ESRD (case-control study: OR: 1.02, 95% CI: 0.77–1.37; meta-analysis: OR: 1.07; 95% CI: 0.97–1.18). Co-dominant, dominant, and recessive model results were also not significant. No known environmental factors moderated the effect of AGTR1 A1166C on CKD in our gene-environment interaction analysis. Sensitivity analysis showed an AGTR1 A1166C-CKD association in Indian populations (OR: 1.46, 95% CI: 1.26–1.69), but not in East Asian or Caucasian populations. Additional South Asian studies will be required to confirm the potential role of this polymorphism in CKD.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2018) conducted a meta-analysis in Chronic kidney disease (CKD) and end-stage renal disease (ESRD) (n=14,823). AGTR1 A1166C (rs5186) C allele polymorphism vs. AGTR1 A1166C A allele (or AA genotype) was evaluated on Chronic kidney disease (CKD) risk (allele model: C vs. A) (OR 1.07, 95% CI 0.97–1.18). The AGTR1 A1166C C allele was not associated with chronic kidney disease risk overall.
Synapse has enriched 10 related papers. Consider them for comparative context: